0001493152-20-012555.txt : 20200702 0001493152-20-012555.hdr.sgml : 20200702 20200702171706 ACCESSION NUMBER: 0001493152-20-012555 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200701 FILED AS OF DATE: 20200702 DATE AS OF CHANGE: 20200702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Diaz-Mitoma Francisco CENTRAL INDEX KEY: 0001701865 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37769 FILM NUMBER: 201010823 MAIL ADDRESS: STREET 1: 222 THIRD STREET, SUITE 2241 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VBI Vaccines Inc/BC CENTRAL INDEX KEY: 0000764195 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 THIRD STREET STREET 2: SUITE 2241 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-830-3031 MAIL ADDRESS: STREET 1: 222 THIRD STREET STREET 2: SUITE 2241 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: SciVac Therapeutics Inc. DATE OF NAME CHANGE: 20150717 FORMER COMPANY: FORMER CONFORMED NAME: LEVON RESOURCES LTD. DATE OF NAME CHANGE: 20100910 FORMER COMPANY: FORMER CONFORMED NAME: LEVON RESOURCES LTD DATE OF NAME CHANGE: 19850305 4 1 ownership.xml X0306 4 2020-07-01 0 0000764195 VBI Vaccines Inc/BC VBIV 0001701865 Diaz-Mitoma Francisco C/O VBI VACCINES INC., 222 THIRD STREET, STE 2241 CAMBRIDGE MA 02142 0 1 0 0 Chief Medical Officer Option (Right to Buy Common Shares) 2.99 2020-07-01 4 A 0 167150 0 A 2030-07-01 Common Shares 167150 167150 D Exercise price represents the volume weighted average closing price of the Issuer's common shares on the Nasdaq Capital Market for Grant Date (as defined below) and the four (4) trading days preceding the Grant Date. The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on July 1, 2020 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated July 1, 2020 (the "Option Agreement"). 25% of the options vest and become exercisable on the one-year anniversary of the Grant Date, with the remaining 75% of the options vesting and becoming exercisable in 24 equal monthly installments beginning on the first day of the month following the one-year anniversary of the Grant Date, subject to the reporting person's employment on the relevant vesting date. The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. /s/ Francisco Diaz-Mitoma 2020-07-02